Markets:

Overview

News

Currencies

International

Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

536.59 -14.88 (-2.70%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

These 3 Stocks Lowered Their Share Counts Drastically in Q1 ↗

June 09, 2026

Pinterest, Southwest Airlines, and United Therapeutics each executed significant share repurchases in Q1 2026, reducing their outstanding share counts by 16%, 5%, and 3.2%, respectively.

Via MarketBeat

1 Cash-Producing Stock with Exciting Potential and 2 We Ignore

June 03, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

Topics Energy

What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗

May 30, 2026

Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies.

Via The Motley Fool

Topics Regulatory Compliance

United Therapeutics (NASDAQ:UTHR) Shares Dip After Q1 2026 Earnings Miss ↗

May 06, 2026

Via Chartmill

United Therapeutics Corp. (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate ↗

March 28, 2026

Via Chartmill

United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate ↗

March 04, 2026

Via Chartmill

2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down

May 29, 2026

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...

Via StockStory

Topics Credit Cards

5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call

May 13, 2026

United Therapeutics' first quarter results fell below Wall Street's revenue and earnings expectations, but the market responded favorably. Management attribu...

Via StockStory

Topics Earnings

UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook

May 07, 2026

Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the market’s revenue expectations in Q1 CY2026, with sales falling 1.6% year on year to...

Via StockStory

UTHR Q1 2026 Earnings Transcript ↗

May 06, 2026

UTHR Q1 2026 Earnings Transcript

Via The Motley Fool

United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings

May 06, 2026

Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 1.6% year on year to $781....

Via StockStory

Topics Artificial Intelligence

United Therapeutics (UTHR) Q1 Earnings Report Preview: What To Look For

May 04, 2026

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting results this Wednesday before market hours. Here’s what to look for. United Therape...

Via StockStory

Topics Artificial Intelligence

The eVTOL Era is Beginning With Uber and Joby Aviation: What Investors Need to Know ↗

April 29, 2026

The eVTOL market is preparing for takeoff in 2026, but which stocks will win out over the long term?

Via The Motley Fool

UTHR Q4 2025 Earnings Transcript ↗

April 21, 2026

UTHR Q4 2025 Earnings Transcript

Via The Motley Fool

3 Reasons Investors Love United Therapeutics (UTHR)

April 17, 2026

Since April 2021, the S&P 500 has delivered a total return of 68.6%. But one standout stock has more than doubled the market - over the past five years, Unit...

Via StockStory

Topics Stocks

3 Market-Beating Stocks for Long-Term Investors

April 07, 2026

Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca...

Via StockStory

Topics Energy

United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF

March 31, 2026

In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso...

Via MarketMinute

Chips Down, Ackman Up: How Iran, the Fed, and a Viral Post Defined Monday's Market ↗

March 31, 2026

Via Chartmill

Topics Economy

Why United Therapeutics (UTHR) Stock Is Up Today

March 30, 2026

What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 12.7% in the afternoon session after the company announced its TETON-...

Via StockStory

Traders are paying attention to the gapping stocks in Monday's session. ↗

March 30, 2026

Via Chartmill

1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm

March 30, 2026

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...

Via StockStory

Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs Peers

March 23, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

2 Mid-Cap Stocks for Long-Term Investors and 1 We Avoid

March 19, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...

Via StockStory

1 Cash-Heavy Stock to Target This Week and 2 That Underwhelm

March 18, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Via StockStory

Topics Firearms

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗

March 16, 2026

Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.

Via The Motley Fool

Topics Regulatory Compliance

This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗

March 16, 2026

Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.

Via The Motley Fool

Topics Regulatory Compliance Supply Chain

Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks

March 09, 2026

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ...

Via StockStory

Topics Artificial Intelligence

2 Cash-Producing Stocks to Keep an Eye On and 1 That Underwhelm

February 26, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Why United Therapeutics (UTHR) Shares Are Sliding Today

February 26, 2026

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 7.2% in the afternoon session after the company reported fourth-quarter financial results that missed revenue expectations,...

Via StockStory

Topics Earnings

The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough

February 26, 2026

United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company...

Via Finterra

Topics Earnings Economy Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.